Diabetes News and Research

Latest Diabetes News and Research

Non-hormonal menopausal medication improves mood and hot flashes

The first real-world study of the FDA-approved non-hormone treatment fezolinetant found the menopausal medication improved hot flashes, depression and anxiety in women, according to industry-sponsored research being presented Sunday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Common plasticizer may trigger lifelong anxiety-related behavioral changes

Male rats that were exposed to the widely used plasticizer di-(2-ethylhexyl) phthalate (DEHP) during early development exhibited increased anxiety behavior as adults, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Hormone-disrupting chemicals found in breast milk and infants' urine

Endocrine-disrupting chemicals (EDCs) that interfere with hormones were found in breast milk and in the urine of children from birth up to 6 months, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Longer hormone exposure may increase thyroid cancer risk in women

Longer lifetime exposure to female hormones may increase the risk of thyroid cancer in women, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Puerto Rico sees sharp rise in adolescent type 1 diabetes

The incidence of type 1 diabetes among teens in Puerto Rico more than doubled from 2009 to 2021 and remained elevated through 2024, with an average annual increase of 4.1 percent, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Study finds gaps in guideline-based testosterone prescribing practices

Only a small number of men who were prescribed testosterone therapy received appropriate, guideline-concordant diagnostic testing, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill, by Sophia Sinha, M.D., clinical assistant professor at the University of Michigan in Ann Arbor, Mich.

14 Jun 2026

Testosterone benefits older men with T2D risk when combined with lifestyle changes

Testosterone treatment may improve body composition, glucose metabolism and sexual desire in some older men at high risk of type 2 diabetes (T2D), but the benefits require engagement in a lifestyle program, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Eliminating dietary sugar may disrupt gut health and promote inflammation

Eliminating sugar from your diet may be more detrimental than previously thought, according to an animal study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Diabetes raises mortality risk after solid-organ transplantation

People with an organ transplant who develop or have existing diabetes are more likely to die than those without diabetes, according to a comprehensive analysis of solid-organ transplant recipients, which is being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

GLP-1 therapy associated with more dizziness and fainting

Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications.

14 Jun 2026

Physical activity declines after starting GLP-1 obesity treatments

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

AI model could improve screening for primary aldosteronism

A study of a new AI model examining 30 years of routine electronic health records (EHR) data could improve screening for primary aldosteronism, a leading cause of high blood pressure that is often unrecognized but increases patients' risk of cardiovascular complications, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

New guideline recommends tailored care for precocious puberty

Some subgroups of children with precocious puberty-such as older girls with slowly progressing puberty-may not need the same level of testing or treatment, according to a new Endocrine Society Clinical Practice Guideline released today.

14 Jun 2026

Comprehensive food regulations lower obesity risk among children

Chile's complementary set of policies targeting food products high in fat, salt and sugar plausibly reduces the risk of school age children being overweight or having obesity, finds a study published in The Lancet.

11 Jun 2026

Scientists uncover protein-folding mechanism linked to diabetes progression

Origami masters turn simple sheets of paper into ornate sculptures. In the origami of life, our cells must fold proteins into specific three-dimensional shapes before they can carry out their biological jobs.

11 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Trial finds prunes do not outperform calcium and vitamin D for male bone density

A one-year randomized trial found that daily prune supplementation did not improve total or lumbar spine bone mineral density in older men susceptible to, or with, osteopenia. Although some bone turnover biomarkers differed between prune and control groups, these changes did not translate into measurable bone density benefits beyond calcium and vitamin D3 supplementation.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

New stretchable bioelectronics advance wearable and implantable health monitoring

Wearable and implantable biosensors have the potential to revolutionize health care by diagnosing, monitoring, and even treating a wide range of health conditions.

11 Jun 2026

Circadian clock protein BMAL1 enhances inflammatory responses in immune cells

Daily life is shaped by the solar day, influencing when we wake up, eat, work, and sleep. Inside the body, a similar internal timing system -present in nearly every cell- known as the circadian clock, synchronizes many biological functions such as sleep, metabolism, hormone release, and even the immune system's activity.

11 Jun 2026